{
  "source": "PA-Med-Nec-Voquezna.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2328-3\nProgram Prior Authorization/Medical Necessity\nMedication Voquezna® (vonoprazan)\nP&T Approval Date 3/2024, 6/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nVoquezna is a potassium-competitive acid blocker indicated for healing and to maintain healing\nof all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis\nand non-erosive gastroesophageal reflux disease in adults, and in combination with amoxicillin\nor amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection\nin adults.\n2. Coverage Criteriaa:\nA. Erosive Esophagitis and Non-Erosive Gastroesophageal Reflux Disease (GERD)\n1. Authorization\na. Voquezna will be approved based on both of the following:\n(1) One of the following:\n(a) For the treatment or maintenance of erosive esophagitis\n(b) For the treatment of non-erosive gastroesophageal reflux disease (GERD)\n-AND-\n(2) History of failure, contraindication, or intolerance to one of the following:\n(a) omeprazole\n(b) pantoprazole\n(c) rabeprazole\nAuthorization will be issued for 9 months.\nB. Helicobacter Pylori\n1. Authorization\na. Voquezna will be approved based on both of the following:\n(1) For the treatment of Helicobacter pylori (H. pylori) in combination with amoxicillin\nor amoxicillin and clarithromycin\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) History of failure, contraindication, or intolerance to one of the following:\n(a) omeprazole\n(b) pantoprazole\n(c) rabeprazole\nAuthorization will be issued for 1 month.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (",
    "apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Voquezna [package insert]. Buffalo Grove, IL: Phathom Pharmceuticals Inc.; November 2023.\n2. Chey, WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J\nGastroenterol 2017; 112:212–238; doi: 10.1038/ajg.2016.563; published online 10 January 2017.\nProgram Prior Authorization/Medical Necessity – Voquezna\nChange Control\n3/2024 New program.\n6/2024 Updated step one options to include omeprazole and pantoprazole.\n1/2025 Added coverage for GERD based on updated labeling.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}